Adjuvant treatment with anti‐PD‐1 in acral melanoma: A nationwide study

Key Points

Recurrence-free survival in acral melanoma patients was 14.8 months, significantly shorter than the 37.4 months in cutaneous melanoma patients.
A total of 1958 patients were included, with 86 having acral melanoma and 1872 having cutaneous melanoma.
Analysis used multivariable Cox regression to adjust for confounders in clinical outcomes after treatment with anti-PD-1 therapy. The study highlights clinical disparities in melanoma types, particularly in response to treatment.

We only have this paper's title and publication details.

Nationwide study investigates recurrence-free survival after adjuvant anti-PD-1 treatment in acral melanoma, suggesting efficacy concerns remain.

No takes yet. Share an insight, caveat, or question.

Bloem et al. (2024) studied this question.

View Full Paper

Ask AI

Bookmark

Share